Annexon, Inc. insider trading
Every open-market purchase and sale by Annexon, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Annexon, Inc.’s insiders pay?
From April 18, 2022 to September 25, 2026, 10 insiders reported 26 open-market purchases and 25 sales not made under a pre-set plan in Annexon, Inc. Twelve months after each purchase was reported, the shares were −62.6% against the S&P 500 on average (median −69.8%), over 7 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −58.0% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 15, 2023 into $5,118 by November 2, 2026, −16.6% a year. It held shares 94% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,604 (+18.3% a year), and held throughout $19,158 (+19.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Carson William H. | Director | 16 | −67.1% (6) | 0% | 0 | — | May 13, 2026 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 0 | — | — | 6 | −57.4% (3) | March 4, 2026 |
| Satter Muneer A | Director | 6 | −35.5% (1) | 0% | 0 | — | May 29, 2026 |
| Love Douglas | PRESIDENT AND CEO | 2 | — | — | 3 | −55.5% (2) | September 25, 2026 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 0 | — | — | 5 | −51.6% (2) | March 4, 2026 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 0 | — | — | 5 | −68.0% (2) | March 4, 2026 |
| Artis Dean Richard | EVP & CHIEF SCIENTIFIC OFFICER | 0 | — | — | 3 | — | March 4, 2026 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | 0 | — | — | 3 | — | March 4, 2026 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | 1 | — | — | 0 | — | May 30, 2023 |
| Choi Jung | Director | 1 | — | — | 0 | — | December 3, 2025 |
When several insiders traded Annexon, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Annexon, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 3 selling crowds, −29.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2026 | 2 buying | −30.3% | not yet | not yet |
| February 27, 2026 | 5 selling | −13.8% | −24.0% | not yet |
| February 29, 2024 | 4 selling | −18.3% | −4.1% | −70.6% |
| February 28, 2023 | 3 selling | −55.2% | −59.0% | −25.7% |